Is Erythritol the New Aspartame?
No, erythritol is not "the new aspartame"—emerging evidence from 2025 reveals concerning cardiovascular and cerebrovascular risks with erythritol that were not previously recognized, making it potentially more problematic than aspartame for certain populations, particularly those with cardiovascular risk factors.
Critical Safety Distinction
While both are FDA-approved non-nutritive sweeteners, recent high-quality research demonstrates fundamental differences in their safety profiles:
Erythritol's Emerging Cardiovascular Concerns
The most recent 2025 data shows erythritol causes direct adverse effects on brain microvascular endothelial cells at concentrations equivalent to a single artificially sweetened beverage (30g) 1. Specifically, erythritol:
- Increases intracellular reactive oxygen species production by 204% (vs 105% in controls)
- Reduces nitric oxide production (5.8 vs 7.3 µmol/L)
- Increases endothelin-1 production (34.6 vs 26.9 pg/mL)
- Blunts tissue plasminogen activator release in response to thrombin
- Impairs eNOS activation through altered phosphorylation patterns
These mechanisms directly contribute to increased risk of ischemic stroke and cardiovascular events 1.
Aspartame's Established Safety Profile
In contrast, aspartame has been studied in over 100 trials with decades of use 2. The only established contraindication is phenylketonuria, and reported adverse effects are limited to rare cases of thrombocytopenia 2. Aspartame does not demonstrate the endothelial dysfunction or prothrombotic effects seen with erythritol.
Metabolic Effects: A Mixed Picture
Where Erythritol Shows Advantages
- Satiety effects: Erythritol significantly decreases ghrelin compared to aspartame and increases satiety measures 3
- Glucose/insulin: No effect on glucose or insulin levels 4
- Tolerability: Better gastrointestinal tolerance than other sugar alcohols due to nearly complete absorption and urinary excretion 5
Critical Caveat on Observational Data
While some studies suggest erythritol may benefit weight management [@4,5@], observational studies show positive associations between plasma erythritol and obesity/cardiometabolic disease 5. However, this likely reflects dysregulated pentose phosphate pathway metabolism rather than dietary erythritol intake itself.
Clinical Recommendation Algorithm
For patients WITHOUT cardiovascular risk factors:
- Either sweetener is acceptable
- Erythritol may offer modest satiety advantages 3
- Avoid aspartame only if phenylketonuria present 2
For patients WITH cardiovascular disease, stroke history, or multiple risk factors (hypertension, diabetes, obesity):
- Avoid erythritol given direct endothelial dysfunction and prothrombotic effects 1
- Aspartame remains acceptable (unless phenylketonuria)
- Consider stevia or monk fruit as alternatives 2
For patients with diabetes specifically:
- Both have minimal glycemic impact 4
- Cardiovascular risk profile should guide choice (favor aspartame if CV risk present)
Common Pitfalls to Avoid
- Assuming all non-nutritive sweeteners are equivalent: The 2025 endothelial cell data 1 demonstrates erythritol has unique vascular toxicity not shared by aspartame
- Relying on older safety data: Most erythritol safety assessments predate 2025 mechanistic studies showing cardiovascular harm
- Ignoring dose: A single artificially sweetened beverage can contain 30g erythritol—enough to cause measurable endothelial dysfunction 1
- Confusing endogenous with exogenous erythritol: Elevated plasma erythritol from metabolic dysfunction differs from dietary intake, but both may contribute to risk 5
The Bottom Line
Erythritol is not simply "the new aspartame"—it represents a distinct cardiovascular risk that aspartame does not carry. The 2025 mechanistic data showing direct brain microvascular endothelial dysfunction 1, combined with observational cardiovascular event associations [@10,11@], positions erythritol as potentially more concerning than aspartame for morbidity and mortality outcomes. While erythritol may offer metabolic advantages in healthy individuals, its use should be avoided in anyone with cardiovascular risk factors until long-term safety trials definitively establish its safety profile 6.